Bio

Clinical Focus


  • Dermatology

Academic Appointments


Professional Education


  • Residency:Stanford University Hospital and Clinics - Dermatology Department (2010) CA
  • Residency:Univ of California San Francisco (2005) CA
  • Internship:Univ of California San Francisco (2003) CA
  • Medical Education:UCSF-School of Medicine (2002) CA
  • Fellowship:Stanford University (2007) CA
  • Board Certification: Dermatology, American Board of Dermatology (2011)

Research & Scholarship

Clinical Trials


  • Grafting of Epidermolysis Bullosa Wounds Using Cultured Revertant Autologous Keratinocytes Not Recruiting

    The term epidermolysis bullosa (EB) is used to describe a group of genetic skin diseases associated with skin weakness, blisters, and chronic wounds. "Revertant mosaicism" means that there are two genetically different populations of cells due to spontaneous mutations. Some EB patients have normal, non-fragile skin patches which may be areas of revertant mosaicism. In the revertant areas, the proteins function normally, like non-EB skin. In this study, we plan to culture cells from the revertant areas and graft them on to the wounded areas.

    Stanford is currently not accepting patients for this trial. For more information, please contact Emily S Gorell, MS, 650-721-7166.

    View full details

  • Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa Recruiting

    Recessive dystrophic epidermolysis bullosa (RDEB) is a severe inherited blistering skin disease caused by absence of a protein known as type VII collagen. Patients with RDEB develop large, severely painful blisters and open wounds from minor trauma to their skin. This trial will create a graft, which the investigators call "LEAES," of the patient's own skin that has been genetically engineered in the investigators lab to express this missing protein. The purpose of this study is to achieve proof-of-concept for this general approach to cell-based gene therapy in humans and to set the stage for further therapeutic extension in RDEB. The investigators will basically take a subject's own cells, correct them in culture, and then transplant the corrected cells back onto them.

    View full details

Publications

Journal Articles


  • An open-label study to evaluate sildenafil for the treatment of lymphatic malformations JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY Danial, C., Tichy, A. L., Tariq, U., Swetman, G. L., Khuu, P., Leung, T. H., Benjamin, L., Teng, J., Vasanawala, S. S., Lane, A. T. 2014; 70 (6): 1050-1057

    Abstract

    Lymphatic malformations can be challenging to treat. Mainstay interventions including surgery and sclerotherapy are invasive and can result in local recurrence and complications.We sought to assess the effect of 20 weeks of oral sildenafil on reducing lymphatic malformation volume and symptoms in children.Seven children (4 boys, 3 girls; ages 13-85 months) with lymphatic malformations were given oral sildenafil for 20 weeks in this open-label study. The volume of the lymphatic malformation was calculated blindly using magnetic resonance imaging performed before and after 20 weeks of sildenafil. Lymphatic malformations were assessed clinically on weeks 4, 12, 20, and 32. Both the physician and parents evaluated the lymphatic malformation in comparison with baseline.Four subjects had a lymphatic malformation volume decrease (1.0%-31.7%). In 2 subjects, despite a lymphatic malformation volume increase (1.1%-3.7%), clinical improvement was noted while on sildenafil. One subject had a 29.6% increase in lymphatic malformation volume and no therapeutic response. Lymphatic malformations of all 6 subjects who experienced a therapeutic response on sildenafil softened and became easily compressible. Adverse events were minimal.A randomized controlled trial will be necessary to verify the effects of sildenafil on lymphatic malformations.Sildenafil can reduce lymphatic malformation volume and symptoms in some children.

    View details for DOI 10.1016/j.jaad.2014.02.005

    View details for Web of Science ID 000336030400023

    View details for PubMedID 24656411

  • Rapidly Involuting Congenital Hemangioma Associated with Profound, Transient Thrombocytopenia PEDIATRIC DERMATOLOGY Rangwala, S., Wysong, A., Tollefson, M. M., Khuu, P., Benjamin, L. T., Bruckner, A. L. 2014; 31 (3): 402-404

    Abstract

      Rapidly involuting congenital hemangioma (RICH) is an uncommon, often high-flow vascular tumor that presents at birth and involutes within the first year of life. It is clinically and histologically distinct from infantile hemangioma, kaposiform hemangioendothelioma, and tufted angioma, the latter two being associated with Kasabach-Merritt phenomenon. We present a female infant with RICH and profound, transient thrombocytopenia and review the extent and clinical course of thrombocytopenia in the context of congenital vascular tumors.

    View details for DOI 10.1111/j.1525-1470.2012.01827.x

    View details for Web of Science ID 000334884300044

  • Multiple Eruptive Pilomatricomas in a 9-Year-Old Boy with Glioblastoma PEDIATRIC DERMATOLOGY Hollmig, S. T., Tollefson, M. M., Kim, J., Khuu, P. 2013; 30 (6): 756-758

    Abstract

      A 9-year-old male presented to our dermatology clinic with a recent history of developing numerous cutaneous pilomatricomas, and was subsequently discovered to have sustained a recurrence of his glioblastoma multiforme. Immunohistochemical staining of a representative pilomatricoma and his original brain tumor revealed upregulation and nuclear localization of beta-catenin, a sign associated with poor prognosis in glioblastoma. We hypothesize that the development of multiple pilomatricomas may have been a hallmark of this patient's tumor recurrence and provide support for a recent report of an association between multiple pilomatricomas and gliomatosis cerebri.

    View details for DOI 10.1111/j.1525-1470.2011.01714.x

    View details for Web of Science ID 000326969100088

    View details for PubMedID 22304393

  • Clofarabine in refractory Langerhans cell histiocytosis PEDIATRIC BLOOD & CANCER Rodriguez-Galindo, C., Jeng, M., Khuu, P., McCarville, M. B. 2008; 51 (5): 703-706

    Abstract

    Patients with multi-system Langerhans cell histiocytosis (LCH) who progress on frontline therapy have a dismal outcome. Responses to cladribine have been reported in relapsed LCH, but there are no well defined salvage regimens for LCH is refractory to therapy. The next generation deoxyadenosine analog, clofarabine, has demonstrated activity in patients with leukemia that is refractory to salvage regimens, including other nucleotide congeners; however, no experience exist on the use of clofarabine in LCH. In this report we describe significant single agent activity of clofarabine in disseminated LCH refractory to salvage regimens, including cladribine.

    View details for DOI 10.1002/pbc.21668

    View details for Web of Science ID 000259465400033

    View details for PubMedID 18623218

Stanford Medicine Resources: